(4-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)(4-phenylcyclohexyl)methanone | 1159096-75-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: (4-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)(4-phenylcyclohexyl)methanone
• 英文别名: [4-(1H-benzimidazol-2-yl)piperidin-1-yl]-(4-phenylcyclohexyl)methanone
• CAS: 1159096-75-9
• 化学式: C₂₅H₂₉N₃O
• 分子量: 387.525
• InChiKey: RJXRMGQTHWHLCZ-UHFFFAOYSA-N

物化性质

• 沸点：
  653.3±55.0 °C(predicted)
• 密度：
  1.191±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  49
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-苯基-环己烷羧酸 、 2-(4-哌啶)-1H-苯并咪唑 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 (4-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)(4-phenylcyclohexyl)methanone
  参考文献：
  名称：

  A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties

  摘要：

  We have been exploring the potential of 5-HT2B antagonists as a therapy for chronic heart failure. To assess the potential of this therapeutic approach, we sought compounds possessing the following attributes: (a) potent and selective antagonism of the 5-HT2B receptor, (b) low impact of serum proteins on potency, and (c) desirable pharmacokinetic properties. This Letter describes our investigation of a biphenyl benzimidazole class of compounds that resulted in 5-HT2B antagonists possessing the above attributes. Improving potency in a human serum albumin shift assay proved to be the most significant SAR discovery. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.02.126

文献信息

• A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties
  作者：Neil Moss、Younggi Choi、Derek Cogan、Adam Flegg、Andreas Kahrs、Pui Loke、Orietta Meyn、Raj Nagaraja、Spencer Napier、Ashley Parker、J. Thomas Peterson、Philip Ramsden、Christopher Sarko、Donna Skow、Josh Tomlinson、Heather Tye、Mark Whitaker

  DOI：10.1016/j.bmcl.2009.02.126

  日期：2009.4

  We have been exploring the potential of 5-HT2B antagonists as a therapy for chronic heart failure. To assess the potential of this therapeutic approach, we sought compounds possessing the following attributes: (a) potent and selective antagonism of the 5-HT2B receptor, (b) low impact of serum proteins on potency, and (c) desirable pharmacokinetic properties. This Letter describes our investigation of a biphenyl benzimidazole class of compounds that resulted in 5-HT2B antagonists possessing the above attributes. Improving potency in a human serum albumin shift assay proved to be the most significant SAR discovery. (C) 2009 Elsevier Ltd. All rights reserved.